fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Erectile dysfunction drugs appear to reduce the risk of Alzheimer’s

Written by | 13 Feb 2024

Phosphodiesterase type 5 inhibitors (PDE5Is) used to treat erectile dysfunction might also reduce the risk of Alzheimer’s disease onset, researchers reported on Feb. 7, 2024 in Neurology. “Although… read more.

New guidelines aim to elevate comprehensive care for people with severe epilepsy

Written by | 11 Feb 2024

The National Association of Epilepsy Centers (NAEC) has developed updated guidelines that outline the comprehensive services and resources epilepsy centers should provide to improve quality of care for… read more.

Variety of drugs top ibuprofen for migraine

Written by | 7 Dec 2023

Triptan, ergot and anti-emetic medications appear to be two to five times more effective than ibuprofen for treating migraine, researchers reported on Nov. 29, 2023 in Neurology. “There… read more.

Can sound stimulation lessen long-term concussion symptoms?

Written by | 26 Nov 2023

New research indicates that acoustic stimulation of the brain may ease persistent symptoms in individuals who experienced mild traumatic brain injury in the past. The study, which is… read more.

Cheap medicines prevented migraine as well as expensive ones

Written by | 21 Nov 2023

Migraine is more than just a headache. Often the pain is accompanied by nausea, vomiting, light sensitivity, and sound sensitivity. Chronic migraine can be disabling and may prevent… read more.

Does COVID-19 or COVID-19 vaccination worsen migraines?

Written by | 2 Nov 2023

Research published in the European Journal of Neurology indicates that COVID-19 and COVID-19 vaccination have negligible effects on migraine severity. Among 550 adults who had received migraine-related care at a… read more.

Investigative epilepsy drug shows significant efficacy

Written by | 13 Oct 2023

Among patients with treatment resistant epilepsy, the investigative drug XEN1101 has reduced seizure frequency by over 50%. And in some patients it stops them completely. Researchers reported these… read more.

Telecare cuts costs, boosts quality of life for dementia patients

Written by | 11 Oct 2023

A UCSF telecare program that improves outcomes for patients with dementia and lightens the load for unpaid caregivers also has the surprising bonus of cutting Medicare costs, according… read more.

Study shows nearly 300% increase in ADHD medication errors

Written by | 29 Sep 2023

Attention-deficit/hyperactivity disorder (ADHD) is among the most common pediatric neurodevelopmental disorders. In 2019, nearly 10% of United States (U.S.) children had a diagnosis of ADHD. Approximately 3.3 million… read more.

CHMP positive for Finlee + trametinib for the treatment of low and high grade glioma – Novartis

Written by | 26 Sep 2023

On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.

Brain stimulation improves walking in Parkinson’s patients

Written by | 10 Sep 2023

A new approach to electrically stimulating the brain can improve the gait of people with Parkinson’s disease (PD), according to a study by Shinshu University in Japan. The… read more.

Could fathers’ epilepsy treatment affect childhood development?

Written by | 8 Sep 2023

European medicines regulators are studying the potential risk of neurodevelopmental disorders (NDDs) in children conceived by fathers taking valproate, an epilepsy medicine. Preliminary data suggest a possible association… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.